OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder

INTRODUCTION: A prespecified pooled analysis of two placebo-controlled, phase 3 trials evaluated whether the number of prior anticholinergics used or reason for their discontinuation affected the treatment response to onabotulinumtoxinA 100U in overactive bladder (OAB) patients with urinary incontin...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int J Clin Pract
Egile Nagusiak: Sievert, K-D, Chapple, C, Herschorn, S, Joshi, M, Zhou, J, Nardo, C, Nitti, V W
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BlackWell Publishing Ltd 2014
Gaiak:
Urology
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4282287/
https://ncbi.nlm.nih.gov/pubmed/24754838
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12443
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak